Navigation Links
Carl Zeiss Continues on Track to Further Growth and Investment
Date:12/13/2012

STUTTGART, Germany, December 13, 2012 /PRNewswire/ --

Strong Portfolio Offsets Cyclical Fluctuations in the Semiconductor Manufacturing Technology Business Group

The Carl Zeiss Group ended fiscal year 2011/12 with a two percent increase in revenue to a total of EUR 4.163 billion (prior year*: EUR 4.084 billion). EBIT totaled EUR 420 million (prior year*: EUR 608 million). "2011/12 was a very successful fiscal year for Carl Zeiss. "We have surpassed the figure we forecast last year: revenue is slightly above the equivalent total in the prior year," said Dr. Michael Kaschke, President and CEO of Carl Zeiss. "What is particularly notable is that our strong portfolio has enabled us to successfully offset the cyclical downturn in the revenue of the Semiconductor Manufacturing Technology business group. This would not have been possible just a few years ago."  

In 2011/12 Carl Zeiss hired 900 new recruits worldwide and increased its investments in research and development by 14 percent. Investments in property, plant and equipment totaled EUR 289 million, allowing the company to modernize and expand its global infrastructure.

*Calculated on a like-for-like basis

More information at http://www.zeiss.de/press

Carl Zeiss

The Carl Zeiss Group is an international leader in the fields of optics and optoelectronics. In fiscal year 2011/12 the company's approx. 24,000 employees generated revenue of about 4.163 billion euros. In the markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics, Carl Zeiss has contributed to technological progress all over the world for more than 160 years.

The Carl Zeiss Group develops and produces planetariums, eyeglass lenses, camera and cine lenses and binoculars as well as solutions for biomedical research, medical technology and the semiconductor, automotive and mechanical engineering industries. Carl Zeiss is present in over 40 countries around the globe with about 40 production sites, over 50 sales and service locations and approximately 20 research and development centers. Carl Zeiss AG is fully owned by the Carl Zeiss Stiftung (Carl Zeiss Foundation). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany.

Press contact
Jörg Nitschke, Carl Zeiss, Konzernkommunikation, Pressesprecher,
Phone +49(0)7364 20-3242, Email: joerg.nitschke@zeiss.com



'/>"/>
SOURCE Carl Zeiss AG
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accelr8 to Hold 2012 Annual Meeting of Shareholders; Product Development Continues with Launch Expected in 2015
2. FUJIFILM Continues To Build 3D Digital Roadmap To Womans Imaging
3. Fujifilm Continues To Grow Its Family Of DR Portables
4. Isis To Receive $1.25 Million Payment As Pfizer Continues Development Of EXC 001
5. Philips continues to improve access to treatment for common cause of death in the U.S. with the delivery of its one-millionth AED
6. PathGroup Unveils a New Look; Continues to Expand Footprint
7. Brainlab Continues to Advance Global Treatment Access and Consistency in Cancer Care Centers
8. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
9. Top OTC Brand deploys Semantelli AETracker to monitor Adverse Events in Facebook
10. Novo Nordisk introduces HemaGo, a mobile application to track hemophilia treatment, bleeding episodes and life events
11. FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... Viverae ® , a leader in workplace wellness technology, ... Watson Campaign Automation, implementing behavioral messaging within the ... experience. Through digital engagement, the platform prompts members to ... The enhanced experience drives engagement by focusing on the ... in their journey to health. Unlike ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
(Date:4/18/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded to ... will present preclinical data supporting the use of SPR741 ... Gram-negative infections at the 27th European Congress of Clinical ... Vienna, Austria . ... "Our ongoing preclinical research ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... As part of the nationwide ... honor the victims of the Holocaust and Nazi persecution, Center for Medicine after ... Auschwitz on its CMATH Champions trip to Germany and Poland next week. , The ...
(Date:4/24/2017)... TX (PRWEB) , ... April 24, 2017 , ... The ... the glitterati, those unreal icons inhabiting the rarified air of pop and film stardom.(1) ... paparazzi and anyone snapping pictures: the smile. Grins now run the gamut from being ...
(Date:4/24/2017)... Calif. (PRWEB) , ... April 24, 2017 , ... The ... $1.6 million in charitable dental services to 1,961 people during the April 22-23 event ... at no charge to Californians who experience barriers to care, CDA Cares educates the ...
(Date:4/24/2017)... ... 24, 2017 , ... Veteran Theresa James awoke to the sound of her ... In “Healing Tears,” James depicts every parent’s worst nightmare, when her three children were ... conversations and situations throughout my divorce,” James said. “After the death of my children, ...
(Date:4/24/2017)... Boca Raton, Florida (PRWEB) , ... April 24, ... ... that develops a variety of unique liquid food supplements, announced its popular products ... of nutritional products. , ALP Nutrition® prioritizes the use of premium natural ...
Breaking Medicine News(10 mins):